Avutometinib Combo Approval Signals “Exciting Time” in KRAS-Mutated LGSOC

Avutometinib plus defactinib (Avmapki Fakzynja Co-pack) may offer a “huge change” in the treatment paradigm for patients with low-grade serous ovarian cancer (LGSOC) harboring KRAS mutations, according to Rachel N. Grisham, MD.

In a conversation with CancerNetwork® following the FDA accelerated approval of avutometinib/defactinib in KRAS-mutated LGSOC, Grisham, section head of Ovarian Cancer and director of Gynecologic Medical Oncology at MSK Westchester of Memorial Sloan Kettering Cancer Center, detailed how this regulatory decision may improve outcomes for this patient population.

Highlighting results from the phase 2 RAMP 201 trial (NCT04625270), Grisham described how the avutometinib combination may effectively lead to tumor shrinkage.2 In particular, she discussed findings presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO) showing a median duration of response exceeding 31 months in patients who received the regimen.

Transcript:

This is such an exciting time for our patients with recurrent low-grade serous ovarian cancer who have been looking for more effective treatment strategies. It's been so difficult for us to treat our patients with these therapies that we know ahead of time are often going to have disappointing response rates. Now, this approval of avutometinib and defactinib is based on the RAMP 201 study, where we saw that patients who harbored a KRAS mutation had a 44% response rate in the recurrent setting.

To be able to offer our patients an effective treatment that actually shrinks their disease is a huge change in the paradigm of how we treat this disease. Another very exciting thing that was seen in the RAMP 201 study is the duration of response. Our patients who were treated with this combination who had a KRAS mutation had a median duration of response of over 31 months on the previously presented results from SGO. It's reassuring to be able to see that many of our patients who respond to this therapy will be able to be maintained on it for long periods of time.

References

1. FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. News release. FDA. May 8, 2025. Accessed May 12, 2025. https://tinyurl.com/ywyd4ps3
2. Grisham RN, Nieuwenhuysen EV, Aghajanian C, et al. Avutometinib + defactinib in recurrent low-grade serous ovarian cancer (ENGOT-ov60/GOG-3052/RAMP 201): dose intensity and subgroup analysis. Presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO); Seattle, WA, March 14-17, 2025.